Raphael J. Mannino - Jun 19, 2021 Form 4 Insider Report for Matinas BioPharma Holdings, Inc. (MTNB)

Role: Chief Scientific Officer
Signature: /s/ Keith A. Kucinski, attorney-in fact for Raphael J. Mannino
Stock symbol: MTNB
Transactions as of: Jun 19, 2021
Transactions value $: $0
Form type: 4
Date filed: 6/24/2021, 05:35 PM
Next filing: Sep 14, 2021

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	MTNB	Common Stock, par value $0.0001 per share	Other	$0	+8K	+0.56%	$0.00	1.44M	Jun 19, 2021	Direct	F1
transaction	MTNB	Common Stock, par value $0.0001 per share	Conversion of derivative security	$0	+20K	+1.39%	$0.00	1.46M	Jun 19, 2021	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	MTNB	Series B Preferred Stock	Conversion of derivative security	$0	-10	-100%	$0.00^*	0	Jun 19, 2021	Common Stock	20K	$0.50	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Stock dividend, payable to all holders of record of Series B Preferred Stock of 400 shares of Common Stock for each share of Series B Preferred Stock.
F2	On June 19, 2021, pursuant to the Certificate of Designations of Preferences, Rights and Limitations of the Series B Preferred Stock (the "Certificate") of the Issuer, all shares of Series B Convertible Preferred Stock were mandatorily converted into shares of the Issuer's common stock. Each share of Series B Convertible Preferred Stock converted into 2,000 shares of the Issuer's common stock. The shares of Series B Convertible Preferred Stock were convertible at any time, at the holder's election, or upon certain mandatory conversion events set forth in the Certificate. The Series B Convertible Preferred Stock had no expiration date.

Content

Stock dividend, payable to all holders of record of Series B Preferred Stock of 400 shares of Common Stock for each share of Series B Preferred Stock.

On June 19, 2021, pursuant to the Certificate of Designations of Preferences, Rights and Limitations of the Series B Preferred Stock (the "Certificate") of the Issuer, all shares of Series B Convertible Preferred Stock were mandatorily converted into shares of the Issuer's common stock. Each share of Series B Convertible Preferred Stock converted into 2,000 shares of the Issuer's common stock. The shares of Series B Convertible Preferred Stock were convertible at any time, at the holder's election, or upon certain mandatory conversion events set forth in the Certificate. The Series B Convertible Preferred Stock had no expiration date.